The article, published by The Defender, expresses concern about the FDA's approval of a Phase 1 trial for a self-amplifying mRNA vaccine targeting the H5N1 bird flu virus. The vaccine, developed by Arcturus Therapeutics, is funded by the U.S. government and the Bill & Melinda Gates Foundation. Critics, including immunologists and epidemiologists, argue that the self-amplifying mRNA technology, which allows the vaccine's RNA to replicate within the body, poses significant safety risks, potentially leading to long-term immune system disruption and even hybridization with other viruses. The article questions the involvement of government agencies and private foundations in the development of these vaccines, suggesting a potential agenda to create a new pandemic.